Cite
HARVARD Citation
Triebwasser, M. et al. (2021). Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatric blood & cancer. 68 (7), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Triebwasser, M. et al. (2021). Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatric blood & cancer. 68 (7), p. n/a. [Online].